LaserGen, Inc. is an emerging biotechnology company focused on commercializing novel technologies for DNA sequencing. Ideally situated in the Texas Medical Center in Houston and through strategic collaboration, technology development, and license agreements with Baylor College of Medicine and Rice University, LaserGen has developed a proprietary platform for DNA sequencing of whole genomes. The combination of the company’s Cyclic Reversible Termination (CRT) and Pulsed Multiline Excitation (PME) technologies enables development of a high-throughput system for sequencing. The system will provide new capabilities at significant cost savings and greater efficiency compared to other technologies. LaserGen’s system is expected to have broad applications in the research and clinical markets. LaserGen was founded in 2002 by Dr. Michael Metzker, who invented the PME method along with Nobel Prize Laureate Robert F. Curl, Jr., Ph.D and their colleagues. The concept that emerged was a four-laser instrument with superior sensitivity and specificity, thereby allowing for the potential of direct DNA sequencing. In 2005, LaserGen scientists made a key discovery in reversible terminator technology that has led to the development of Lightning Terminators. Since that discovery, RD efforts have been focused on development of the Company’s reagent business, enabling faster, cheaper, and more accurate genome sequencing than any existing technology. LaserGen has a highly skilled team of chemists, biologists, and engineers. Our team is our biggest asset, continually driving LaserGen’s technology forward. LaserGen is funded through small business and research grants from the National Human Genome Research Institute, the Texas Emerging Technology Fund (TETF), and several angel investors.